Drug Profile
Research programme: autoimmune and inflammatory disease therapeutics - Cangene
Alternative Names: IGIV - CangeneLatest Information Update: 11 Jul 2012
Price :
$50
*
At a glance
- Originator Cangene Corporation
- Class Immunoglobulins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation
Most Recent Events
- 10 Jul 2012 Discontinued - Preclinical for Autoimmune disorders in Canada (IV)
- 10 Jul 2012 Discontinued - Preclinical for Inflammation in Canada (IV)
- 29 May 2012 Preclinical development is ongoing in Canada